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Abstract  
FGFR3 is one of the most frequently mutated genes in bladder cancer (BLCA) and a driver of 
an oncogenic dependency. Here, we report that only the most common recurrent FGFR3 
mutation, S249C (TCC → TGC), represents an APOBEC-type motif and is likely caused by 
the APOBEC-mediated mutagenic process, accounting for its over-representation. We 
observed significant enrichment of APOBEC mutational signature and over-expression of 
AID/APOBEC gene family members in bladder tumors with S249C compared to tumors with 
other recurrent FGFR3 mutations. Analysis of replication fork directionality suggests that the 
coding strand of FGFR3 is predominantly replicated as lagging strand template that could 
favour formation of hairpin structures facilitating mutagenic activity of APOBEC enzymes. In 
vitro APOBEC deamination assays confirmed S249 as an APOBEC target. We also found 
FGFR3-S249C mutation to be common in three other cancer types with APOBEC mutational 
signature, but rare in urothelial tumors without APOBEC mutagenesis and in two diseases 
likely related to aging. 
Patient summary: We propose that APOBEC-mediated mutagenesis can generate clinically 
relevant driver mutations even within suboptimal motifs, such as in the case of FGFR3-S249C, 
one of the most common mutations in bladder cancer. Knowledge about etiology of this 
mutation will improve our understanding of molecular mechanisms of bladder cancer. 
 
Keywords: Bladder cancer, upper urinary tract cancer, FGFR3 mutation, APOBEC, Lynch 
syndrome  
Text 
FGFR3 (fibroblast growth factor receptor 3) is one of the most frequently mutated genes in 
bladder cancer (BLCA). Over 65% of non-muscle-invasive bladder cancer (NMIBC) and 15% 
of muscle-invasive bladder cancer (MIBC) carry an FGFR3 mutation driving an oncogenic 
dependency [1,2]. We reviewed publicly available data for 10,032 bladder tumors (Fig.S1 and 
Table S1) and identified 56 different FGFR3 mutations, including 14 recurrent mutations 
(detected in ≥ 2 samples, Table S2, Fig.1A). The most common was S249C mutation (TCC → 
TGC), representing 62% of all recurrent FGFR3 mutations. We wondered whether this over-
representation of FGFR3-S249C was associated with some specific mutational processes. 
Considering all mutational signatures [3], the S249C (TCC → TGC) is most similar to an 
APOBEC-type mutation (TCN → T[G/T]N, where N = any nucleotide, but most frequently A 
or T). Of all recurrent FGFR3 mutations, only S249C presents an APOBEC-type motif 
(Fig.1A). APOBEC (apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like) 
mutational signature accounts for ~30% and 65% of all mutations in NMIBC and MIBC, 
respectively [2,4]. Thus, we hypothesized that FGFR3-S249C mutation might be caused by the 
activity of APOBEC enzymes. 
We analyzed mutational signatures in NMIBC based on RNA-seq data and observed that only 
the APOBEC-type signature (S3 scores, represent APOBEC signature fraction score and 
mutation calling from RNA-seq data, Supplementary method) was significantly higher in 
tumors with S249C mutation compared to tumors with other recurrent FGFR3 mutations 
(Fig.1B), while other RNA-seq derived mutational signatures did not differ between these 
groups (Fig.S2). 
We also analyzed APOBEC mutation load in MIBC in The Cancer Genome Atlas (TCGA). 
Even though only 13% of MIBC had recurrent FGFR3 mutations (compared to 67% in 
NMIBC), S249C was found in similar proportions (60%) in MIBC and NMIBC. We were 
unable to demonstrate a significant association between overrepresentation of S249C mutation 
and APOBEC mutation load in the much smaller MIBC subset of tumors with recurrent FGFR3 
mutations (n = 52, Fig.S3) compared to NMIBC (n = 227). To consider higher heterogeneity 
of MIBC than NMIBC, we took advantage of the previous stratification of MIBC tumors as 
APOBEC-high, APOBEC-low and APOBEC-no [2]. We observed a significantly higher 
proportion of S249C mutation in tumors with any APOBEC activity (APOBEC-high and low) 
compared to APOBEC-no tumors (Fig.1C). In addition, considering the two groups of tumors 
with APOBEC activity, APOBEC mutation load was overall significantly higher in tumors 
with S249C mutation compared to tumors bearing other recurrent FGFR3 mutations (Fig.1D). 
Thus, it appears that FGFR3-S249C mutation is favored in tumors with APOBEC activity;  
 
Figure 1. FGFR3-S249C mutation as a possible outcome of APOBEC-mediated mutagenesis. 
(A) The rates and distribution of FGFR3 mutations in 10,032 BLCA patients.  Shown are 
recurrent FGFR3 mutations observed in at least two BLCA patients, with some patients 
carrying several FGFR3 mutations. The mutation numbering corresponds to FGFR3 IIIb as 
the main isoform in cells of epithelial origin. The FGFR3 IIIb isoform contains two more amino 
acids than the FGFR3 IIIc isoform. The full list of recurrent FGFR3 mutations is provided in 
Table S2. The most common recurrent FGFR3 mutation hotspot, S249 (TCC) is the only motif 
possibly targeted by APOBEC-mediated mutagenesis. (B) RNA-seq derived APOBEC mutation 
score (S3) in 227 NMIBC tumors in relation to recurrent FGFR3 mutations. P-value is for 
Mann-Whitney U tests between two groups. (C) Distribution of recurrent FGFR3 mutations in 
52 TCGA MIBC tumors classified as APOBEC-high, APOBEC-low and APOBEC-no; P-value 
is for Fisher’s exact test comparing APOBEC-no group versus APOBEC presenting groups 
(high and low). (D) APOBEC mutagenesis pattern (log10) in 42 TCGA MIBC tumors in 
relation to recurrent FGFR3 mutations in APOBEC-high and APOBEC-low groups. Box-plots 
show group medians and 50% of all the values, dots represent individual values and group 
means. P-value is for nested ranks test between all groups of samples. (E) Predicted secondary 
structure (Mfold) for FGFR3 sequence, with R248 and S249 mutation hotspots marked. 
APOBEC deamination assays show successful generation of DNA breaks at the cysteine 
positions only within probe 1 (positive control) and probe 2 in which intact S249 site is located 
within the single-stranded 5-nucleotide loop, but not within probes 3 and 4, which lack S249 
site (negative control). Additional information and secondary structures of all the probes are 
provided in Fig. S6. (F) Replication fork directionality (RFD) profiles around FGFR3 gene in 
HeLa and K562 cell lines determined based on mapping of Okazaki fragments to C (Crick) and 
W (Watson) DNA strands. Red (blue) RFD profiles mark regions where the Watson (Crick) 
strands are replicated majority as lagging strand templates. Arrows indicate the position of 
FGFR3 gene (GRCh37_Chr 4: 1,795-1,811 kb) which is predominantly replicated from 
lagging strand template in both cell types.  
BLCA, bladder cancer; NMIBC, non-muscle-invasive bladder cancer; MIBC, muscle-invasive 
bladder cancer.  
 
APOBEC-low MIBC and NMIBC may have lower background noise than APOBEC-high 
tumors, making the S249C enrichment more noticeable than in APOBEC-high tumors. 
To identify a possible APOBEC mutagen for the FGFR3-S249C mutation, we analyzed 
expression levels of all 11 genes from the AID/APOBEC gene family (Fig.S4). Comparing 
tumors with FGFR3-S249C vs. other recurrent FGFR3 mutations, only expression of 
APOBEC3A and APOBEC3H was significantly different in NMIBC and only expression of 
APOBEC3A and APOBEC3B in APOBEC-low MIBC (Fig.S5).  
APOBEC-mediated mutagenesis preferentially targets lagging DNA strand templates [5], 
which is consistent with transient excess of single-stranded DNA (ssDNA) during replication 
process. The efficiency of APOBEC mutagenesis has also been associated with the propensity 
of ssDNA to form hairpins, with some APOBEC3 enzymes, such as APOBEC3A, 
preferentially targeting loops in the stem-loop structures [6]. Notably, residue S249 is located 
in the center of a 5-nucleotide ssDNA loop (Fig.1E). Accordingly, in vitro deamination assays 
confirmed S249 as a target of the APOBEC deamination activity (Fig.1E). We also performed 
in silico analysis of genome-wide replication fork directionality (RFD) data in two cancer cell 
lines [7] (Fig.1F). We conclude that the coding strand of FGFR3 is replicated predominantly 
as the lagging strand template, thereby creating an opportunity for ssDNA to form a hairpin 
and expose S249 to mutagenic activity of APOBEC enzymes. 
Interestingly, dominance of FGFR3-S249C mutation was reported in sporadic, low-grade 
upper-tract urothelial carcinomas (UTUC), also enriched in APOBEC-signature mutations. In 
contrast, when associated with Lynch syndrome (LS), an inherited disorder caused by germline 
mutations in DNA mismatch repair genes, UTUC lack APOBEC-signature mutations and 
FGFR3-S249C but have high frequency of FGFR3-R248C further supporting the link between 
APOBEC and over-representation of FGFR3-S249C [8] (Fig.2A).  
We also tested whether the link between the APOBEC-mediated mutagenesis and FGFR3-
S249C mutation exists in other cancers. We reviewed publicly available data (Table S1) and 
catalogued FGFR3 mutations in some other cancer types, including head and neck cancer 
(HNSCC), cervical cancer (CESC) and non-small cell lung cancer (NSCLC) (Fig.2B-D), in 
which enrichment of APOBEC-signature mutations has been reported [3]. FGFR3-S249C 
mutation was enriched in all these conditions (Fig. 2B-D). Because APOBEC3s are interferon 
stimulated genes [9], it is possible that in virally-induced cancers, such as HNSCC and CESC, 
and in BLCA that may also have infectious etiology, FGFR3-S249C mutation is generated as 
a result of APOBEC3 induction in the course of immune response.  
FGFR3 mutations are also detected in benign skin tumors (nevus and seborrheic keratosis) and 
germline bone disorders (thanatophoric dysplasia). However, in these conditions that have no 
infectious etiology and have been linked with other causes such as aging [10], R248C (GCG 
→ GTG) is the predominant FGFR3 mutation (Fig.2E-F).  
 Figure 2. FGFR3 mutation spectrum across several cancer types, benign skin tumors and bone 
disorders. (A-F) The rates and distribution of FGFR3 mutations in patients with sporadic (n = 
82) and Lynch syndrome-associated (n = 17) UTUC, HNSCC (n = 1983), CESC (n = 792), 
NSCLC (n = 5121), benign skin tumors (n = 616) and bone disorders (thanatophoric dysplasia) 
(n = 447). Among all recurrent FGFR3 mutations only FGFR3-S249C mutation motif (TCC) 
is the possible target of APOBEC-mediated mutagenesis. (A-E) The mutation numbering 
corresponds to FGFR3 IIIb as the main isoform in cells of epithelial origin. (F) The mutation 
numbering corresponds to FGFR3 IIIc as the main isoform in chondrocytes. The full list of 
recurrent FGFR3 mutations with numbering corresponding to both FGFR3 IIIb and IIIc 
isoforms is provided in Table S2. 
HNSCC, head and neck squamous cell carcinoma; CESC, cervical squamous cell carcinoma 
and endocervical adenocarcinoma; NSCLC, non-small cell lung cancer; benign skin tumors 
include seborrhoeic keratosis and epidermal nevus; bone disorders include thanatophoric 
dysplasia-I (TD-I) and II (TD-II). FGFR3 mutations found in cancers and benign skin tumors 
are somatic, those found in bone disorders are germline but identical to somatic mutations in 
tumors. 
 
We found that FGFR3-S249C protein has similar potential to transform NIH-3T3 cells 
compared to FGFR3 with a recurrent non-APOBEC-type mutation Y375C (TAT → TGT, 18% 
of BLCA, Fig.1A), and FGFR3 with either mutation activates the same transcriptional 
regulators in bladder cancer cell lines suggesting their comparable functions (Fig.S7). Thus, 
the over-representation of S249C in APOBEC-related cancers is likely due to increased 
mutation rate caused by APOBEC3 activity rather than increased tumorigenicity of the S249C 
mutation. 
In conclusion, we demonstrate that FGFR3-S249C mutation, despite being a less frequent 
APOBEC-motif, is likely caused by the APOBEC-mediated mutagenic activity in BLCA and 
other conditions. Further investigations should explore whether the APOBEC mutagenesis 
alone generates FGFR3-S249C mutation or it requires other factors. Our results also pave the 
way for further studies to explore other APOBEC-induced driver mutations considering 
broader definition of motifs targeted by the APOBECs. 
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         1. Supplementary methods 
1.1 Data collection 
     1.1-1) Databank for FGFR3 mutation spectrum was compiled from three sources: 1) 
COSMIC portal (https://cancer.sanger.ac.uk/cosmic) [1], 2) cBioPortal for Cancer Genomics 
(http://www.cbioportal.org/) [2,3], and 3) manual search. We extracted well-documented 
FGFR3 mutation data in tumors from COSMIC portal and selected 4 cancers and several skin 
diseases (seborrhoeic keratosis and epidermal nevus) with a significant number of recurrent 
FGFR3 mutations. As cBioPortal is another important public source of mutation data, we 
double-checked the records for the selected cancers in cBioPortal. We included the latest data 
or, if there was an overlap (ie. TCGA-BLCA), we combined the data between these two major 
sources, otherwise we manually added non-redundant data from cBioPortal. As neither 
COSMIC nor cBioPortal included data from the two large cohorts of non-muscle-invasive 
bladder cancer (NMIBC) [4,5], we added them manually. Lastly, we noted that although 
FGFR3 mutations were common in bone disorders (thanatophoric dysplasias), no 
systematically pooled data were publicly available. Therefore, we manually reviewed literature 
of thanatophoric dysplasia and catalogued a comprehensive FGFR3 mutational spectrum for 
this disease, with all FGFR3 mutations being germline. One article [6] was excluded, because 
the frequent mutation (G697C) reported in this study was debatable [7] and not observed 
elsewhere. A graphical workflow of data collection and detailed mutation spectrum are 
presented in Fig. S1 and Table S1 (separate Excel file).  
Recent publications reported enrichment of FGFR3-R248C mutation in upper urinary tract 
urothelial cancer (UTUC) with Lynch syndrome where APOBEC signature was very low; in 
contrast, S249C mutation was much more common in the subgroup of UTUC without Lynch 
syndrome that exhibited APOBEC signature [8,9]. We presented the reported data [8] in Fig. 
2A. 
     1.1-2) NMIBC cohort 
The largest NMIBC cohort to date with a total of 476 tumors was published by Hedegaard et 
al [4]. For these tumors we used RNA-Seq derived scores for six mutational signatures, 
including APOBEC-like, S3 scores (227 tumors with mutation load adequate for signature 
extraction, including 136 tumors with FGFR3-S249C mutation and 91 tumors with other 
recurrent FGFR3 mutations) and RNA expression measured as FPKM (270 tumors subjected 
to RNA sequencing, including 161 tumors with FGFR3-S249C mutation and 109 tumors with 
other recurrent FGFR3 mutations).  
     1.1-3) TCGA-MIBC cohort 
Data for the FGFR3 mutation status, log10-transformed APOBEC mutagenesis pattern 
(represented by APOBEC_MutLoad_MinEstimate) and APOBEC mutagenesis category (no, 
low, and high) were available in Table S1 of the TCGA bladder cancer paper [10]. RNA-seq 
data (RSEM) were downloaded from cBioPortal and log2-transformed. There were 52 tumors 
with recurrent FGFR3 mutations: 31 with S249C versus 21 with other mutations; of those - 10 
tumors were classified as APOBEC-no, 24 as APOBEC-low and 18 as APOBEC-high; one 
tumor lacked RNA-seq data and was not used in expression analysis.   
1.2 Deamination assays 
Custom-designed 5’-fluorescein-labeled oligonucleotides (probes 1-4) were purchased from 
Thermo Fisher Scientific. The positive control (probe 1) carrying a TCC motif was previously 
described [11]. The probe 2 included a 25-nucleotide fragment of FGFR3 centered on S249 
(TCC); in negative control probes 3 and 4 the S249 (TCC) sequence was altered to TGG and 
TTG. Probes 2-4 also carry the R248 site (GCG, underlined italics). Deamination is expected 
to affect cytosines within the underlined motifs; additional identical sequences not targeted by 
deamination (small fonts) were added to probes 2-4 to increase their size. 
Probe 1: 
5′-fluorescein - ATTATTATTATTATTCCCAATTATTTATTTATTTATTTATTT   
Probe 2: 
5′fluorescein – attattattaCCACAGAGCGCTCCCCGCACCGGCCattattattat - 3'  
Probe 3: 
5′-fluorescein - attattattaCCACAGAGCGCTGGGCGCACCGGCCattattattat - 3' 
Probe 4:  
5′-fluorescein – attattattaCCACAGAGCGCTTGGCGCACCGGCCattattattat - 3' 
The C-terminally Myc-DDK tagged APOBEC3A expression construct (NM_145699) in the 
pCMV6 vector was purchased from OriGene (Rockville, MD). The construct was transiently 
transfected with Lipofectamine 3000 (Thermo Fisher Scientific) into human embryonal kidney 
HEK293-T cells, seeded in 175 cm2 flasks (Corning) at a density of 4×106 cells/20 mls. Cells 
were harvested and lysed in CelLytic M buffer (Sigma) 24 hrs post-transfection. To increase 
concentration of the recombinant APOBEC3A protein, whole-cell lysates were passed through 
purification step using c-Myc tagged Protein Mild Purification Kit (MBL, Japan) and treated 
with RNAase A at 37℃ for 30 minutes.  
Deamination reactions were performed using a previously described protocol [12]. Briefly, 
each 10 µl reaction mix contained 1 µl of a probe (5-10 picomoles), 4 µl of semi-purified 
APOBEC3A recombinant protein (~ 0.25 ug) and 1 µl of 10x deamination buffer (100 µl of 
100 mM Tris/HCl, pH 7.5; 100 µl of 500 mM NaCl; 10 µl of 10 mM DTT and 790 µl of water) 
and 4 µl H2O. Reactions were incubated in water bath at 37°C for 2 hrs, treated with Uracil 
DNA Glycosylase (UDG) for 40 min at 37°C, followed by addition of 0.6 N NaOH for 20 min 
at 37°C. After adding 20 µl of 2x RNA loading dye (Thermo Fisher Scientific), the reactions 
were heated at 95°C for 2-3 min. Of the total reaction volume, 15 µl aliquot was resolved on 
15% TBE-urea polyacrylamide gel (Life Technologies) at 150 V for 1 hr and 30 min at room 
temperature in 1x TBE buffer. Gels were imaged with Gel Doc (Bio-Rad) using 
Fluorescein/UV settings. Another set of 15 µl aliquots from the same reactions was separately 
resolved on 4-12% Tris-glycine SDS polyacrylamide gel (Life Technologies) for detection of 
APOBEC3A with an anti-DDK antibody (F7425; Lot # 086M4803V; Sigma) using the ECL 
Plus Western blotting detection system (GE Healthcare Life Sciences).  
1.3 Analysis of secondary structure of single-stranded DNA (ssDNA) 
Mfold tool with default parameters for DNA folding (http://unafold.rna.albany.edu/?q=mfold) 
[13] was used to evaluate secondary structure of all 4 probes used for deamination assays, 
focusing on 25 nucleotide sequences centered on FGFR3-S249C as input.  
1.4 Functional comparison of FGFR3 with S249C versus Y375C mutations 
NIH-3T3 cells (murine fibroblasts) transiently transfected with expression constructs for the 
human FGFR3 with S249C or Y375C mutations, positive control with high transforming 
potential (HRAS-Q61R) or the mock control pcDNAI-Neo plasmid (Neo) were established as 
previously described [14]. Pools of transfected cells were established by two weeks of selection 
on 800 µg/ml G418, followed by culturing in DMEM with 10% fetal bovine serum (FBS), 2 
mM glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, and 400 µg/ml G418. The ability 
of the expressed proteins to transform NIH-3T3 cells was evaluated by the anchorage 
independent growth of the cells in soft agar. Cells (3x104) were seeded in 12-well plates 
containing DMEM with 10% FBS and 1% agar, in triplicates. The plates were incubated for 
two weeks and colonies larger than 50 µm in diameter, as measured with a phase-contrast 
microscope equipped with a measuring grid, were counted. 
To identify genes regulated by FGFR3 with different mutations, MGH-U3 and UMUC-14 
bladder cancer cells endogenously expressing FGFR3-Y375C and FGFR3-S249C, respectively, 
were transfected for 72 hrs with three FGFR3 siRNAs (described in Mahe et al [15]). mRNA 
was extracted and purified with the RNeasy Mini kit (Qiagen). Total RNA (200 ng) from 
control and siRNA-treated MGH-U3 and UMUC-14 cells was analyzed with the Affymetrix 
human exon 1.0 ST array and the Affymetrix U133 plus 2 array, respectively, as previously 
described [15]. Experiments using MGH-U3 cells have been described by Mahe et al [15] and 
the microarray data were available from GEO (https://www.ncbi.nlm.nih.gov/geo/) under 
accession number GSE84733. Data for the UMUC-14 cells were generated in the current work. 
The LIMMA algorithm was used to identify genes differentially expressed between FGFR3 
siRNA-treated (3 different siRNAs) and Lipofectamine-treated cells (3 replicates) [16]. The p-
values were adjusted for multiple testing by Benjamini–Hochberg FDR method. Genes with a 
log2 fold-change ≥ 0.58, in a positive or negative direction and an FDR p-value below 5%, 
were considered to be differentially expressed. An analysis of the two lists of FGFR3-regulated 
genes using the upstream regulator function of the Ingenuity Pathway Analysis (IPA) software 
identified upstream regulators activated and inhibited by FGFR3-S249C and FGFR3-Y375C.  
1.5 Replication fork directionality (RFD) profiling  
We used data for RFD profiling in two human cancer cell lines - HeLa and K562 cells [17,18]. 
In these reports, the authors isolated and sequenced Okazaki fragments (OK-Seq) to determine 
the whole-genome RFD profiles of a given cell model. RFD was computed as the difference 
between the proportions of Crick (C) and Watson (W) okazaki fragments in 1 kb windows as: 
RFD = (C - W)/(C + W). A region majority replicated by right-ward replication forks (Watson 
strand as lagging strand template) was considered as “+” RFD, and a left-ward replication forks 
(Crick strand as lagging strand template) was considered as “-” RFD. This directionality 
determined which strand would be favored as lagging strand template. Analysis of RFD 
profiles showed that FGFR3-S249C mutation was located in the lagging strand template, 
known to be preferentially targeted by APOBEC mutagenesis  [19,20].  
1.6 Statistical analysis 
Non-parametric Mann-Whitney U test was performed to compare APOBEC 
signature/mutagenesis values and expression of APOBEC genes between groups of tumors 
with FGFR3-S249C and other recurrent FGFR3 mutations. The mixed model extension of 
Mann-Whitney U test, i.e. nested ranks test, was used for similar analysis with multiple groups. 
Dunnett’s test was performed to compare the number of soft agar colonies after overexpression 
of FGFR3-S249C, FGFR3-Y375C, and negative and positive controls in NIH-3T3 cells. 
Analyses were performed using R version 3.5.2, package ‘nestedRanksTest’, version 0.2. 
Fisher’s exact test was used to compare differences in distribution of categorical variables. 
Plots were generated with Microsoft Excel 2016 (pie charts) or R version 3.5.2 using package 
‘easyGgplot2’, version 1.0.0.9000. Figures were assembled in Adobe Illustrator.  
2. Supplementary Figures 
 
 
  
 
Fig. S1 Workflow of data collection for FGFR3 mutation spectrum. MeSH terms can be found 
in Table S1. BLCA, bladder cancer; HNSCC, head and neck squamous cell carcinoma; CESC, 
cervical squamous cell carcinoma and endocervical adenocarcinoma; NSCLC, non-small cell 
lung cancer; Benign skin tumors include seborrhoeic keratosis and epidermal nevus; Bone 
disorders include thanatophoric dysplasia-I (TD-I) and II (TD-II).  
 Fig. S2 Distribution of mutational signature scores in 227 tumors from patients with non-
muscle-invasive bladder cancer (NMIBC [4]) with recurrent FGFR3 mutations - S249C vs. 
other mutations. Recurrent mutations were defined as those found in at least 2 patients in 
analysis presented in Fig.1A and listed in Table S2. P-values are for Mann-Whitney U test; 
the result for S3 (APOBEC) signature scores is also plotted in Fig. 1B. Box-plots show group 
medians and 50% of all the values, dots represent individual values and group means.  
  
 Fig. S3 Distribution of APOBEC mutational pattern in 52 MIBC [10] patients with recurrent 
FGFR3 mutations - S249C vs. other mutations. Recurrent mutations were defined as those 
found in at least 2 patients in analysis presented in Fig. 1A and listed in Table S2. P-values are 
for Mann-Whitney U test. Box-plots show group medians and 50% of all the values, dots 
represent individual values and group means. 
  
 Fig. S4 Statistical significance for the association between AID/APOBEC gene expression 
(FPKM, log2) and recurrent FGFR3 mutations - S249C vs. other recurrent FGFR3 mutations 
in 270 NMIBC [4] and 41 MIBC (RSEM, log2) [10] patients (24 with APOBEC-low and 17 
with APOBEC-high tumors). Low and high groups correspond to APOBEC-signature mutation 
load, as has been previously defined [10]. Recurrent mutations were defined as those present 
in at least 2 patients in analysis presented in Fig. 1A and listed in Table S2. There are 11 
APOBEC genes that could potentially contribute to APOBEC mutagenesis - AICDA (AID), 
APOBEC1 (A1), APOBEC2 (A2), APOBEC3 (A3A, A3B, A3C, A3D, A3F, A3G and A3H) and 
APOBEC4 (A4) [21]. P-values are for Mann-Whitney U tests between two groups (overall 
NMIBC, APOBEC-low MIBC and APOBEC-high MIBC) or for nested ranks test between all 
groups of MIBC samples. The asterisks with different colors represent P-values for association 
between FGFR3-S249C and indicated genes in different groups. 
  
  
 
 
 
 
Fig. S5 Distribution of expression values for the AID/APOBEC genes significantly associated 
with recurrent FGFR3 mutations - S249C vs. other mutations in 270 NMIBC [4] and 41 MIBC 
[10] patients in analysis presented in Fig. S4. (A) APOBEC3A in NMIBC tumors. (B) 
APOBEC3H in NMIBC tumors. (C) APOBEC3A in MIBC tumors. (D) APOBEC3B in MIBC 
tumors. APOBEC-low and high groups correspond to APOBEC-signature mutation load, as 
has been previously defined [10]. Recurrent mutations were defined as those present in at least 
2 patients in analysis presented in Fig. 1A and listed in Table S2. Box-plots show group 
medians and 50% of all the values, dots represent individual values and group means. P-values 
are for Mann-Whitney U tests between two (comparison was conducted only within APOBEC-
low groups in Fig.S5C-D).  
C 
D 
MIBC with recurrent FGFR3 mutations, n = 41 
 Fig. S6 Mfold analysis of secondary structures of all probes used for deamination assays - S249 
is located within a single-stranded 5-nucleotide loop, while R248 is located within the double-
stranded hairpin stem; shown are central 25 bp nucleotides of each probe. APOBEC-mediated 
mutagenesis is accumulated in ssDNA, preferentially targeting hairpin loops [13,22,23]. Loops 
of more than 3-nt have been shown to aid APOBEC enzyme binding [13,23], with the 
APOBEC3A binding site requiring bent ssDNA [22].  
 Fig. S7 Similar tumorigenic potential of FGFR3 with S249C and Y375C mutations. (A) 
Overexpression of FGFR3-S249C and FGFR3-Y375C in NIH-3T3 cells shows similar 
transformation potential and significantly lower compared to HRAS-Q61R (positive control), 
based on the number of soft agar colonies; Dunnett's multiple comparisons test. Shown are 
mean+/- SD of one representative experiment conducted in triplicate. Three experiments were 
performed with three different pools of transiently transfected cells. (B) Genes affected by 
FGFR3 depletion in human MGHU-U3 and UMUC-14 bladder cancer cells endogenously 
expressing FGFR3-Y375C and FGFR3-S249C, respectively, were identified using expression 
analysis with Affymetrix arrays. Upstream regulators possibly controlling the expression of 
these genes were identified using IPA software. Top 10 most activated vs. most inhibited 
master regulators were compared in both cell lines. The Venn diagram shows a strong overlap 
of the main master regulators modulated by FGFR3 in the same way with either mutation 
suggesting their comparable ability to activate the same main signaling pathways. FGFR3 
exists as two isoforms, FGFR3 IIIb (main isoform in cells of epithelial origin) and FGFR3 IIIc 
(expressed in chondrocytes). Due to difference in the size of an alternatively spliced exon in 
FGFR3 IIIb compared to FGFR3 IIIc, the numbering after S249 shifts by +2. Full list of FGFR3 
mutations and their numbering is provided in Table S2. 
3. Supplementary tables 
 
 
 
Table S1. FGFR3 mutation spectrum in human pan-cancer and benign skin tumors and bone 
disorders among 18,991 individuals. Related to Figure 1A, Figure 2B-F and Supplementary 
Figure 1. This large matrix is available at https://doi.org/10.1016/j.eururo.2019.03.032. 
 
 
 
 
 
 
Table S2. Frequency of recurrent FGFR3 mutations. Related to Figure 1A and Supplementary 
Figure 2B-2F.  
 
*Mutation positions correspond to FGFR3 IIIb, the numbering of FGFR3 IIIc see in the sheet 
of <ReadMeFirst>. Recurrent mutations (n=14) were defined as present in at least 2 of 3712 
patients with bladder cancer (count see in Suppl 2b); One mutations - p.A371A was excluded 
as it was a silent mutation. BLCA, Bladder cancer; HNSCC, Head and neck squamous cell 
carcinoma; CESC,Cervical squamous cell carcinoma and endocervical adenocarcinoma; 
NSCLC, Non-small cell lung cancer; Benign skin tumors, composed of Seborrhoeic keratosis 
and Epidermal nevus; Bone disorders, composed of Thanatophoric dysplasia-I (TD-I) and TD-
II. Codon was shown in bold and mutated nucleotide underlined.  
 MUTATION_CDS  MUTATION_AA* Code_WT Code_Mut
c.746C>G p.S249C 62%(2326) 57%(16) 100%(7) 44%(7) 11%(36) 9%(26) TCC TGC
c.1124A>G p.Y375C 18%(693) / / / 9%(28) 23%(67) TAT TGT 
c.742C>T p.R248C 9%(336) 7%(2) / 25%(4) 37%(122) 46%(134) GCGC GTGC
c.1114G>T p.G372C 5%(177) / / / 6%(20) 2%(6) GGGC GTGC
c.1117A>T p.S373C 1%(56) / / / 6%(20) 1%(2) GAGT GTGT
c.1954A>G p.K652E 1%(51) / / / 9%(30) 13%(38) GAAG GGAG
c.1178C>A p.A393E 1%(37) / / / 2%(5) / GCG GAG
c.1144G>C or c.1144G>A p.G382R 1%(20) 14%(4) / / / / CGGG CC/AGG
c.1955A>T p.K652M 0.3%(12) / / / 21%(69) 1%(2) AAG ATG
c.1954A>C p.K652Q 0.1%(5) / / / / / GAAG GCAG
c.1955A>C p.K652T 0.1%(5) / / / / / AAG ACG
c.1156T>C p.F386L 0.1%(2) / / / / / CTTC CCTC
c.1178C>T p.A393V 0.1%(2) / / / / / GCG GTG
c.1927G>A p.D643N 0.1%(2) / / / / / GGAC GAAC
Pan-cancer and other diseases
Nucleotide context Recurrent FGFR3  mutations
BLCA HNSCC CESC NSCLC Skin Bone (TD)
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1st round review: letter to editor and point by point response 
 
 
 
  
 
 
Paris, January 22th, 2019 
 
 
Ms. No: EURUROL-D-18-01506 
Title: APOBEC-mediated mutagenesis as a likely cause of FGFR3-S249C mutation over-
representation in bladder cancer 
 
Dear Dr. Catto, 
We would like to thank you and the reviewers for considering our manuscript and providing 
constructive comments and suggestions. We have thoroughly revised the paper, included new 
results, and provided point-by-point responses reflecting changes in the manuscript.  
In recent years, APOBEC mutagenesis has been identified as an important molecular feature 
of bladder tumors and disease aggressiveness. Our results on molecular etiology of FGFR3-
S249C, the most common and a clinically relevant FGFR3 mutation, will improve our 
understanding of bladder cancer. 
We expect our paper will be of interest for the broad scientific community, and specifically 
for researchers working on bladder cancer, FGFR3 and APOBEC mutagenesis. 
We hope that after this thorough revision, our work meets the high standards for publication 
in European Urology. 
 
Yours sincerely, 
 
On behalf of the authors,   
 
François Radvanyi  
 
 
Point-by-point response to reviewers  
We thank the reviewers for their constructive comments and suggestions that led to new 
analyses and helped to improve our manuscript. Overall, the data presented in our revised 
manuscript strengthened the hypothesis about the link between APOBEC mutagenic activity 
and over-representation of FGFR3-S249C mutation in BLCA and other conditions.  
 
Comment from Reviewer # 1: 
1. “The authors have attempted to identify a correlation between APOBEC mutational 
signature and FGFR3-S249C mutations in bladder cancer. The authors identified a 
correlation between signature and mutation in patients with non-muscle invasive bladder 
cancer, but are unable to do so in patients with muscle invasive bladder cancer. The 
explanation to why this occurs is anemic and requires further analysis.” 
Response:  
Initially, we focused our analysis on APOBEC signature 13 (TCW->TGW, W=A or T) as the 
closest match for the FGFR3-S249C mutation motif (TCC->TGC). Because this analysis is 
based on assigning statistical probabilities to different signatures and this deconvolution 
process is associated with uncertainties, we initially used only 66 NMIBC samples out of 227 
with FGFR3 mutations. In these 66 samples signature 13 was considered to be dominant. To 
use information from all 227 tumors with FGFR3 mutations, we decided to use estimates for 
total APOBEC mutagenesis.  
In the current version we made the following changes in the analysis: 
1. In NMIBC, we used the total RNAseq-based APOBEC mutation signature score 
(S3) that reflects the global APOBEC activity without distinction between signatures 2 
and 13, allowing us to use information from all 227 NMIBC tumors with FGFR3 
mutations [1]. 
2. For MIBC, a recent bioRxiv manuscript preprint (Alexandrov, 
https://doi.org/10.1101/322859) provided signature 2 and 13 scores for all TCGA 
samples. Our analysis using these scores showed similar trends for both signatures in 
relation to FGFR3-S249C mutation, justifying the use of the combined estimate for 
total APOBEC mutagenesis, which was available in Table S1 (APOBEC induced 
mutation load (P-MACD) variable) of the MIBC TCGA paper, Robertson et al [2]. 
3. We use an existing classification of all MIBC samples as “APOBEC-high, low 
or no” based on the presence of APOBEC-signature mutations provided in Table S1 of 
MIBC TCGA paper, Robertson et al [2]. APOBEC-no tumors have no mutation that 
can be confidently classified as APOBEC-type; the remaining tumors were assigned 
into two groups based on mutation load above and below the median. The use of this 
classification is justified by the striking distribution of FGFR3-S249C mutation in these 
groups (20% in APOBEC-no, 50% in APOBEC-high and 83% in APOBEC-low group, 
Fig. 1C). 
We observed both differences and similarities between NMIBC and MIBC.  
Similarities: 
1. Similar rate of FGFR3-S249C mutation (59.6%) of all recurrent FGFR3 
mutations both in NMIBC and MIBC, despite much higher frequency of tumors with 
recurrent FGFR3 mutations in NMIBC (66.7%) compared to MIBC (12.6%). 
2. Analysis of expression of all 11 genes from the AID/APOBEC family identified 
APOBEC3A as a likely APOBEC enzyme responsible for the FGFR3-S249C mutation 
both in NMIBC and MIBC (Fig.S4 and Fig.S5). 
3. APOBEC-type mutagenesis is significantly higher in FGFR3-S249 tumors 
compared to other recurrent FGFR3 mutations in NMIBC (Fig.1B) and APOBEC-low 
MIBC (Fig.1D). 
Differences: 
1. APOBEC-type mutagenesis is not significantly associated with FGFR3-S249 
compared to other recurrent FGFR3 mutations in MIBC overall and in APOBEC-high 
tumors (Fig.S3 and Fig.1D). This difference could be due to the lower number of 
mutated tumors in MIBC compared to NMIBC (52 MIBC tumors with recurrent 
FGFR3 mutations compared to 227 in NMIBC), or due to higher heterogeneity in 
MIBC.  
These points are now presented in the manuscript: fewer MIBC tumors with recurrent 
FGFR3 mutations compared to NMIBC; heterogeneity of FGFR3 mutations in groups 
based on APOBEC mutation load (Fig. 1C); differences in FGFR3 mutation pattern 
related to APOBEC activity (Fig.1D). These data suggest that APOBEC mutagenesis 
is necessary for generation of FGFR3-S249C mutation; this occurs at the low level of 
APOBEC mutagenesis and likely early in tumor development. In APOBEC-high 
tumors, FGFR3-S249C mutation might be masked by high background of other 
mutations that may appear later in tumor development as a result of multiple factors, 
including genomic instability and treatment.   
2. “Furthermore, attempt to validate the findings from the NMIC cohort in other cancer types 
has resulted in variable findings.” 
Response: 
Our intent in this analysis was to link differential distribution of FGFR3 mutations to their 
possible etiologies. Unlike mutations in TP53 or PIK3CA genes, which are uniformly and 
frequently found in many cancer types, FGFR3 mutations are more context-dependent. The 
FGFR3 mutation rates range from 30% to 50% in bladder cancer, benign skin tumors, while 
being present in less than 3% in other tumor types (Fig. 1A and Fig. 2A-F).  
We suggest that the over-representation of FGFR3-S249C mutation is common in conditions 
linked with APOBEC mutagenesis, such as bladder cancer, head and neck cancer and 
cervical cancer. In other conditions, such as benign skin tumors (seborrheic keratosis) and a 
bone disorders (thanatophoric dysplasia) linked with other mutational processes (aging, UV 
exposure [3–5]), FGFR3-S249C is a rare FGFR3 mutation. 
Two recent publications [6,7] provided additional support for this trend (Fig.2A). In upper 
urinary tract tumors (UTUC) from patients with Lynch syndrome, which present no or low 
APOBEC mutagenesis, FGFR3-S249C mutation is rare, while it is common in sporadic 
UTUC that shows evidence of APOBEC mutagenesis (Fig.2A and Reply Fig. 1A and 1B). 
As this difference was observed in cancers of the same tissue type (the urothelium of the 
upper urinary tract), this provides important support for APOBEC mutagenesis as an 
etiological cause of FGFR3-S249C mutation. 
 
Reply-Figure 1. Distribution of FGFR3 mutations and APOBEC mutational signature in 
UTUC (upper urinary tract urothelial cancer) in patients with and without Lynch syndrome. 
(A) Screenshot from the report of Audenet et al, 2018 CCR (original Fig. 4C); (B) Screenshot 
from the report of Donahue et al, 2018 JCO Precision Oncology (original Fig. 1B).  
3. “Further analysis, in vitro or in vivo, would be important to help understand the 
significance of these findings for clinical use.” 
Response: 
We believe that identifying etiological mechanisms of this mutation that represents almost 
60% of all recurrent FGFR3 mutations both in NMIBC and MIBC, is of clinical significance. 
To improve our understanding of these mechanisms, we have performed several experiments 
and included additional analyses. Specifically, we show that: 1) The presence of S249C 
mutation is significantly associated with APOBEC3A expression both in NMIBC and MIBC 
(Fig.S4 and Fig.S5); 2) FGFR3 with S249C mutation has the same potential as FGFR3 with 
Y375C mutation (the second most frequent mutation found in 18% of tumors, and not an 
APOBEC-type) to transform NIH-3T3 cells and activate the same regulatory pathway in 
bladder cancer cells suggesting lack of functional advantage specifically provided by FGFR3-
S249C (Fig.S7); 3) S249C mutation might be occurring at a high rate because of its position 
within a ssDNA loop of a hairpin, which makes it an efficient target of APOBEC enzymes 
(Fig.1E); 4) Cytosine in the S249 position (TCC) is efficiently deaminated by the activity of 
recombinant APOBEC3A enzyme (Fig.1E). Taken together, our results suggest that the over-
representation of FGFR3-S249C mutation is more likely linked to APOBEC-mediated 
mutagenesis than to a particular functional advantage of this mutation compared to other 
recurrent FGFR3 mutations.  
Comment from Reviewer # 2: 
1. “However, the manuscript is very hard to understand and requires extensive re-writing.  
Response: 
We have significantly revised our manuscript to improve presentation.  
2. Furthermore, the interpretation of the data may be flawed: admittedly, the conclusions may 
be correct but there is not sufficient evidence excluding other explanations for the S249C 
predominance in bladder cancer.” 
Response: 
As provided in response to other questions and reflected in the updated manuscript, we now 
present several new lines of evidence to strengthen our conclusion that APOBEC-mediate 
mutagenesis is a significant contributor to the over-representation of the FGFR3-S249C 
mutation in bladder cancer and other conditions. 
We also provide new functional evidence to exclude that the over-representation results only 
from a functional advantage specifically provided by FGFR3-S249C.  FGFR3 with S249C 
mutation has the same potential as FGFR3 with Y375C mutation (the second most frequent 
mutation found in 18% of tumors, and not an APOBEC-type) to transform NIH-3T3 cells and 
activate the same regulatory pathway in bladder cancer cells (Fig.S7). Although we cannot 
confidently exclude other factors, these results reinforce the likelihood of APOBEC-mediated 
mutagenesis to cause the over-representation of FGFR3-S249C. 
Specific comments 
1. “The authors should cite a recent report that relates signature 13 with PIK3CA and ERBB2 
mutations in bladder cancer (Poulos et al PLOS Genet 2018). In this very broad analysis 
of associations between somatic mutations and mutational signatures in more than 7000 
tumors, the S249C mutation is not identified as significantly associated with APOBEC 
signatures in bladder cancer. Can the authors speculate on the reasons for this 
discrepancy?” 
Response:  
The paper by Poulos et al [8] did not identify association between FGFR3-S249C mutation 
and APOBEC signatures 2 and 13 by comparing 30 tumors with FGFR3-S249C mutation vs. 
368 wild-type tumors of MIBC TCGA (Mann-Whitney P-value = 0.56 for signature 13 and 
0.15 for signature 2, respectively, Table S3 of Poulos paper). This could be because of 
several important differences in our analyses:  
1. Our strongest results are observed in 227 NMIBC with recurrent FGFR3 mutations and 
APOBEC signature scores, while the analysis in Poulos paper [8] was limited by only 50 
MIBC TCGA tumors with FGFR3 mutations and high heterogeneity in APOBEC mutation 
loads in these tumors. 
2. Because we wanted to understand the difference in etiology between FGFR3-S249C 
and other FGFR3 mutations, we performed our analysis only in tumors with recurrent 
FGFR3 mutations, defined as those observed in at least two out of more than 10,000 bladder 
tumors analyzed (Fig 1A and Table S1 and S2). In contrast, the Poulos paper compared 
tumors with a given mutation vs. all other tumors. We performed similar analysis using 
APOBEC signature score (S3) in NMIBC tumors with FGFR3-S249C mutation vs. all other 
tumors. Although the difference was still detectable, it became attenuated (from p=2.45E-05 
to 0.024, Fig.1B and Reply-Figure 2A). Similar analysis in the MIBC TCGA data showed 
that the difference became not significant within the APOBEC-low group (changed from 
p=0.014 to 0.339) and in all groups (changed from p=0.011 to 0.278) (Reply-Figure 2B and 
Fig.1D). 
The comparison with Poulos paper has not been included in the manuscript due to space 
limitation and 10 references allowed in this Brief Communication format.
 
Reply-Figure 2. Distribution of APOBEC mutagenesis between tumors with FGFR3-S249C 
mutations vs. all other tumors. (A) RNA-seq derived APOBEC mutation score (S3) in 341 
NMIBC tumors in relation to FGFR3-S249C mutation. (B) APOBEC mutagenesis pattern 
(log10) in 360 TCGA MIBC tumors in relation to FGFR3-S249C mutation in APOBEC-high 
and APOBEC-low groups. P-values are for Mann-Whitney U tests between two groups or for 
nested ranks test between all groups of samples. NMIBC, non-muscle-invasive bladder 
cancer; MIBC, muscle-invasive bladder cancer.  
2. “The authors should comment on the differences in Figures 1B and 1C between NMIBC 
and MIBC.” 
Response:  
Please see our detailed response to Reviewer 1. 
3. “It would also be important to correlate the occurrence of the signature and FGFR3 
mutation with the corresponding levels of APOBEC mRNA species in tumor tissue when that 
is available.” 
Response: 
Thank you for this suggestion. There are 11 APOBEC genes that could potentially contribute 
to APOBEC mutagenesis - activation-induced deaminase (AICDA (AID)), APOBEC1 (A1), 
APOBEC2 (A2), APOBEC3 (A3A, A3B, A3C, A3D, A3F, A3G and A3H) and APOBEC4 (A4) 
[9]. In NMIBC, only expression of APOBEC3A and APOBEC3H significantly differed, for 
both genes being higher in tumors with S249C compared to tumors with other recurrent 
FGFR3 mutations (Fig.S4 and Fig.S5).  
Similar analysis in MIBC in The Cancer Genome Atlas (TCGA) showed association with 
increased expression of APOBEC3A and APOBEC3B in APOBEC-low tumors with S249C 
compared to tumors with other recurrent FGFR3 mutations (Fig.S4 and Fig.S5). Thus, 
expression of the APOBEC3A appeared to be associated with APOBEC-mediated 
mutagenesis in carriers of FGFR3-S249C mutations both in NMIBC and MIBC.  
In line with this, our in vitro deamination assays with recombinant APOBEC3A protein 
experimentally confirmed S249 as a target of its deamination activity. APOBEC3A might be 
the strongest candidate of all APOBEC3s because it is a typical interferon-stimulated gene 
that is strongly induced by exogenous infectious stimuli [10]. Thus, generation of FGFR3-
S249C mutation could be a collateral effect of the immune response inducing expression of 
APOBEC3A or other APOBEC3s.  
4.   “The paragraph describing the analysis of replication fork directionality (RFD) of the 
FGFR3 gene (p.4, paragraph 1; Fig 1E-F) should be rewritten for clarity. For instance, the 
sentence "Indeed, APOBEC was found to be linked to a strong replicative asymmetry and 
specifically targeting lagging strand template in clinical samples [8]" is confusing: in ref. 8, 
the mutational bias is linked to the transcription sense/antisense strands, not to 
leading/lagging DNA replication strands. The authors should state in the main text that they 
have used available genome-wide RFD data generated by the O. Hyrien lab (current ref. 7 
and Petryk et al, Nat Commun 7:10208; 2016) to analyze in silico whether FGFR3 gene is 
replicated by the leading or lagging strand. The results of this test support replication by the 
lagging strand, which fits with the authors' hypothesis. In this context, it seems very 
important to cite previous studies that link APOBEC mutational signatures to lagging strand 
DNA synthesis: e.g. Haradhvala et al, Cell 2016 and Hoopes et al, Cell Reports 2016.” 
Response:  
This paragraph about replication fork directionality (RFD) was completely rewritten and 
references were cited accordingly. As the format of this Brief Correspondence allows only 10 
references, we cited the article of Wu et al 2018 and Haradhvala et al 2016 in the main text, 
and the works of Petryk et al 2016 and Hoopes et al 2016 were cited in the Supplementary 
Methods. 
 
5 -“It is stated that the S249C mutation does not dominate in benign skin tumors and bone 
dysplasias and that in those conditions an APOBEC mutational signature has not been 
reported. Of course, this signature has not been reported because most likely it has not been 
investigated: in order to identify an APOBEC mutational signature, exome sequencing needs 
to be performed and very few exome sequencing data are available for the two conditions 
mentioned. Following this argument, one could say that the S249C mutation is again better 
selected during the evolution towards malignant diseases rather than in benign non-
neoplastic conditions.” 
Response:  
We agree that we cannot confidently state that there is no reported APOBEC mutational 
signature in seborrheic keratosis (with only one sample sequenced) or in bone dysplasia. 
However, there are several arguments suggesting that these conditions are caused by other 
factors. Aging and cumulative exposure to sunlight are independent risk factors for the 
development of seborrheic keratosis [4,5]. The one seborrheic keratosis tumor that has been 
sequenced [11] showed a UV signature and FGFR3-K652M mutation. FGFR3 mutation in 
thanatophoric dysplasia has been linked to aging [3]. The manuscript has been modified 
accordingly.  
Please also see responses to other questions that indicate that S249 might be an efficient 
target for APOBEC activity due to the secondary structure of the surrounding sequence and 
that FGFR3 is being replicated from lagging strand template. Because the transforming 
properties of FGFR3 with S249C were similar to those of the less frequent mutation, Y375C, 
we suggest that the frequency of FGFR3-S249C mutation is determined by the rate of its 
generation due to APOBEC activity, and not of its selection, at least when compared to 
Y375C mutation. 
6.  “APOBEC-low tumors do present with the S249C mutation. Therefore, it appears that the 
APOBEC-dependent mechanism would be only one of the contributors to the S249C 
mutation. Alternatively, the author's proposal would not be substantiated by the data and - 
for yet unknown reasons - the S249C would be particularly efficient to transform urothelial 
cells rather than other cell types (i.e. skin keratinocytes).” 
Response:  
In fact, this is exactly our point – that APOBEC-low tumors are a distinct group with just 
enough APOBEC expression (mutagenesis) to cause enrichment of FGFR3-S249C mutation 
without high background of mutational noise found in APOBEC-high MIBC tumors that 
would mask this enrichment. The striking distribution of FGFR3-S249C mutation in these 
groups (20% in APOBEC-no, 50% in APOBEC-high and 83% in APOBEC-low group, Fig. 
1C) supports this point.  
In general, enrichment of FGFR3-S249C mutation was found in tumor types that can be 
considered APOBEC-low: NMIBC, APOBEC-low MIBC and sporadic UTUC. Other driver 
mutations in FGFR3 and other genes might be responsible in APOBEC-no and APOBEC-
high tumors. 
Although FGFR3 with S249C mutation is very potent in transforming cells and being 
selected in tumors, we found its potency comparable to that of another recurrent, but much 
less frequent mutation, Y375C (Fig.S7). Thus, we conclude that the initiation rate due to 
APOBEC activity defines the distribution and frequency of FGFR3-S249C mutation. 
Minor comments 
1. “Figure 1A should cite the mutations at the nucleotide rather than the amino acid level in 
order to link with the corresponding explanations in the text.“ 
Response: 
Thank you for this suggestion. We have now added in Fig. 1A the mutation information at 
the nucleotide level, flanking the mutated nucleotide (underlined) and with codons marked in 
bold.  
2. “There are various places in the manuscript where the statements are not clear: APOBEC3 
high vs. low and it is not properly qualified what this refers to. “ 
Response: 
We used an existing definition described in the Table S1 of the MIBC TCGA paper by 
Robertson et al [2]. This table provides classification of all MIBC samples as “APOBEC-
high, low or no” based on the presence of APOBEC-signature mutations. APOBEC-no 
tumors have no mutations that can be confidently classified as APOBEC-type; the remaining 
tumors were assigned into two groups based on mutation load above and below the median. 
We now clearly explain the source of the data and the definitions used.  
3. Comment from Reviewer # 3: 
Major points:  
1. - While there is evidence of association between the specific FGFR3-S249C mutation 
and Sig.13 (the authors were able to produce a significant p-value), this association not 
exclusive to this specific mutation. In fact, as shown in Figure 1, there is still significant 
overlap in the APOBEC Sig.13 frequency and fraction between FGFR3-S249C and other 
FGFR3 mutations in both NMIBC and MIBC. 
Response: 
Mutational signatures represent a statistically defined probability (enrichment) of a mutation 
to occur at a specific motif. However, the utilization of these motifs is very much context-
dependent. As we show by several lines of evidence, the FGFR3-S249C mutation might 
represent a specific case due to an optimal location within an APOBEC-type motif, in the 
loop of a hairpin and within the gene replicated from a lagging strand. All these conditions 
create an opportunity for this site being mutated by APOBECs. Inducible expression of 
APOBEC3s, and particularly of APOBEC3A in the same samples, as well as evidence of 
overall APOBEC-mediated mutagenic activity, increases this chance.  
For this reason and to avoid interpreting Sig 2 and Sig 13 motifs too literally (as TCC->TGC 
mutation fits either of them only partially), we now used an estimate of total APOBEC 
activity as S3 RNA-seq based score in NMIBC and mutation APOBEC mutation load in 
MIBC. The re-analyses did not change our results and conclusions but we believe reduced a 
possible uncertainty associated with deconvolution into signatures 2 and 13 (Fig. 1B, 1D and 
Fig.S3). 
2. - How would the authors explain FGFR3 S249 mutagenesis in the absence of true 
APOPEC Sig.13? Is there is a unique co-mutation pattern that the authors can identify? 
Response: As we mentioned in response to previous questions, mutational signatures are 
derived computationally based on frequency metrics. APOBEC signatures 2 and 13 are 
enriched in specific mutation types (TCW → TTW or TGW), but they don’t exclude other 
patterns, such as (TCN → TTN or TGN). The FGFR3-S249C (TCC → TGC) mutation is one 
of the possible events. We conclude that the high frequency of S249C mutation in APOBEC-
low tumors could be explained by the high rate of its occurrence due to the S249 being an 
optimal target located within a ssDNA loop of the hairpin, availability of APOBEC3A, as 
well as the transforming potential of this mutation leading to its quick enrichment in tumors.  
Using MIBC TCGA dataset described by Robertson et al [2], we identified 6 single 
nucleotide variations (SNVs) co-occurring with FGFR3-S249C, defined as SNVs 
significantly more frequent in FGFR3-S249C subjects (n = 29, with detailed mutation data) 
compared to other TCGA MIBC subjects (Fisher’s exact test, P < 0.05): COMT-K177K, 
EGF-L295L, FSTL5-L375L, NFE2L2-R34G, OCEL1-D118N, and PIK3CA-E545K.  
We mapped these co-mutations to the 29 FGFR3-S249C subjects (Reply-Figure 3). We 
observed no pattern in distribution of these mutations, which may be due to small sample set 
of only 29 tumors.  
 
Reply-Figure 3. SNVs co-occurring with FGFR3-S249C in TCGA MIBC. The mutations in 
bold letters present a common APOBEC motif (TCW, W = T or A). Red and grey boxes 
mark presence and absence of the indicated mutations. 
We did not perform the same analyses for NMIBC subjects because the RNA-seq derived 
mutations may contain more noise.  
3. - Did the authors explore the mutational signature of other commonly co-mutated 
genes with FGFR3 both S249C and others? For example KDM6A, PIK3Ca, STAG2 to name 
a few. 
Response: 
Using MIBC TCGA dataset described by Robertson et al [2], we identified 12 SNVs 
significantly more frequent in subjects with recurrent FGFR3 mutations compared to other 
MIBC subjects (Fisher’s exact test, P < 0.05): COMT-K177K, EGF-L295L, FADD-K149N, 
FSTL5-L375L, HADHB-D185H, HIST1H1C-A180A, KDM6A-X129_splice, OCEL1-D118N, 
PDE4DIP-L527L, PIK3CA-E545K, PTPN12-L595L, and STAG2-R216* (Reply-Figure 4). 
 
Reply-Figure 4. SNVs co-occurring with recurrent FGFR3 mutations in TCGA MIBC. 
Mutations in bold letters present a common APOBEC motif (TCW, W = T or A). In green – 
29 patients with FGFR3-S249C mutation, in blue - 21 patients with other recurrent FGFR3 
mutations. Red and grey boxes mark presence and absence of indicated mutations. 
Among these co-mutations, we observed a total of 22 mutation events corresponding to a 
common APOBEC motif (TCW, W = A or T), including 15 events found in 29 FGFR3-
S249C subjects (overall SNV load = 6144) and 7 events in 21 subjects with other recurrent 
FGFR3 mutations (overall SNV load = 5041). The event frequency of FGFR3 co-mutations 
related to APOBEC in FGFR3-S249C subjects was not statistically significant (FGFR3-
S249C: 15/6144, 0.244%; other recurrent FGFR3 mutations: 7/5041, 0.139%; Fisher’s exact 
test, P = 0.28), but there was a nearly two-fold increase in mutations within APOBEC motifs 
in S249C tumors over tumors with other recurrent FGFR3 mutations. 
We did not perform the same analyses for NMIBC subjects because the RNA-seq derived 
mutations may contain more noise. 
As these results on co-mutations are not statistically significant (might due to limited sample 
size), they were not included in our updated manuscript. 
Minor point:  
- The data could have been presented more clearly to show the exact number of FGFR3 
S249 mutations that are associated with APOBEC Sig.13 and those that are not (instead of 
presenting % only).   
Response: 
Because both APOBEC signatures 2 and 13 showed similar trends for association with 
FGFR3-S249C mutation status (not shown) based on the data of recent bioRxiv manuscript 
preprint (Alexandrov, https://doi.org/10.1101/322859), we now use estimates of the total 
APOBEC mutagenesis for MIBC, without computational deconvolution into signature 2 and 
13, which is not possible to do with confidence in all cases. For this analysis, we used an 
existing set of data defined as APOBEC induced mutation load (P-MACD), available in the 
Table S1 of the MIBC TCGA paper by Robertson et al [2].  
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2nd round review: letter to editor and point by point response 
 
 
 
  
 
 
Paris, March 8th, 2019 
 
 
Ms. No: EURUROL-D-18-01506 
Title: APOBEC-mediated mutagenesis as a likely cause of FGFR3-S249C mutation over-
representation in bladder cancer 
 
Dear Dr. Catto, 
We would like to thank you and the reviewers for positive comments and providing new 
constructive suggestions. We have revised the paper accordingly and provided point-by-point 
responses reflecting changes in the manuscript. The modifications are highlighted in the 
manuscript. 
We hope that after this second revision, our work meets the high standards for publication in 
European Urology. 
 
Yours sincerely, 
 
On behalf of the authors,   
 
François Radvanyi  
 
Point-by-point response to reviewers  
We thank the reviewers for their comments and suggestions that helped to improve our 
manuscript.  
Comment from Reviewer # 1: 
“The authors once again present a brief communication looking at the correlation between 
APOBEC and FGFR3-249c mutations in patients with bladder cancer. They have addressed 
the majority of the reviewers concerns. The in vitro data does add strength to the manuscript. 
Still confusing is the differences found between NMI and MI analysis. The text regarding this 
portion is very confusing. Would recommend revisions to simplify what the authors are trying 
to state or just focus on the NMI samples.” 
Response:  
We thank the reviewer for this encouraging comment. We think that presenting the data for 
both NMIBC and MIBC is important and we did our best to simplify the presentation for 
MIBC. 
Although FGFR3 is less frequently mutated in MIBC compared to NMIBC (13% vs. 67%, 
respectively), we found the same proportion of FGFR3-S249C mutation (60%) among all 
recurrent FGFR3 mutations in both NMIBC and MIBC. This suggests the existence of a 
potential common mechanism between the two tumor types that might be related to S249C 
mutation, specifically. We propose exposure to APOBEC mutagenesis, which generates 
S249C mutation, as a common mechanism. First, we observed an overall significant 
association between APOBEC-mediated mutagenesis and over-representation of S249C 
mutation, even if we had to consider APOBEC stratification as a confounder in MIBC. In 
addition, we found consistent results in both NMIBC and MIBC when looking for APOBEC 
mutagen through gene expression analysis. 
However, we agree that our conclusions made in MIBC are based on a small number of 
FGFR3 mutated samples and still need to be confirmed with a larger sample size in the 
future. 
 
We modified this section (manuscript pages 3-4) as: 
“We observed a significantly higher proportion of S249C mutation in tumors with any 
APOBEC activity (APOBEC-high and low) compared to APOBEC-no tumors (Fig.1C). In 
addition, considering the two groups of tumors with APOBEC activity, APOBEC mutation 
load was overall significantly higher in tumors with S249C mutation compared to tumors 
bearing other recurrent FGFR3 mutations (Fig.1D). Thus, it appears that FGFR3-S249C 
mutation is favored in tumors with APOBEC activity; APOBEC-low MIBC and NMIBC 
may have lower background noise than APOBEC-high tumors, making the S249C 
enrichment more noticeable than in APOBEC-high tumors.” 
  
Comment from Reviewer # 4: 
“Please see the European Urology guidelines for the presentation of statistics: 
https://doi.org/10.1016/j.eururo.2018.12.014. In particular, please follow guideline 4.1 for 
precision. That includes figures (for example, many of the figures include p values to 
inappropriate precision). 
Moreover, don't report p values for between comparisons and then for the difference between 
comparisons (e.g. figure 1D), report only the latter (i.e. nested ranks test). Please use exact 
statistics for comparisons where there are low cell counts (e.g. figure 1c).” 
Response:  
We have carefully reviewed the recommended European Urology guidelines [1] for the 
presentation of statistics and modified our paper accordingly.  
Detailed changes are stated below: 
a). Report P-value: All the P-values reported in the main figures (Figure 1B, 1C and Figure 
2A) as well as supplementary figures (Figure S2, S3, S5 and Figure S7) were modified with 
the recommended appropriate precision, for instance, < 0.001, 0.004, 0.045, 0.13, 0.3, 1. 
b). Report percentage: All the percentages presented in our manuscript, Figure 1A and Figure 
2A-F were reported to two significant figures, for example, 75%, 3.4%, 0.13%. 
According to guideline section 3.1 about accepting a null hypothesis, we modified one 
statement interpreting result of Figure S3. We changed the sentence “Analysis of APOBEC 
mutation load in all tumors with recurrent FGFR3 mutations did not show association with 
S249C mutation status (Fig.S3).” to the current one (manuscript page 3) “We were unable to 
demonstrate a significant association between overrepresentation of S249C mutation and 
APOBEC mutation load in the much smaller MIBC subset of tumors with recurrent FGFR3 
mutations (n = 52, Fig.S3) compared to NMIBC (n = 227)”.   
We followed the reviewer’s suggestions, and reported only nested rank test P-value in Figure 
1D to make it clear.  
As suggested, for Figure 1C and Figure 2A we now present results for Fisher’s exact test 
instead of Chi-square test, with P-values remaining significant. 
 
Reference 
[1] Assel M, Sjoberg D, Elders A, Wang X, Huo D, Botchway A, et al. Guidelines for 
Reporting of Statistics for Clinical Research in Urology. Eur Urol 2018;75:358–67. 
doi:10.1016/j.eururo.2018.12.014. 
 
